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Abstract
Background: Whole genome sequencing (WGS) is already being used in certain clinical and research settings, but
its impact on patient well-being, health-care utilization, and clinical decision-making remains largely unstudied. It is
also unknown how best to communicate sequencing results to physicians and patients to improve health. We
describe the design of the MedSeq Project: the first randomized trials of WGS in clinical care.
Methods/Design: This pair of randomized controlled trials compares WGS to standard of care in two clinical
contexts: (a) disease-specific genomic medicine in a cardiomyopathy clinic and (b) general genomic medicine in
primary care. We are recruiting 8 to 12 cardiologists, 8 to 12 primary care physicians, and approximately 200 of their
patients. Patient participants in both the cardiology and primary care trials are randomly assigned to receive a family
history assessment with or without WGS. Our laboratory delivers a genome report to physician participants that
balances the needs to enhance understandability of genomic information and to convey its complexity. We provide
an educational curriculum for physician participants and offer them a hotline to genetics professionals for guidance
in interpreting and managing their patients’ genome reports. Using varied data sources, including surveys,
semi-structured interviews, and review of clinical data, we measure the attitudes, behaviors and outcomes of
physician and patient participants at multiple time points before and after the disclosure of these results.
Discussion: The impact of emerging sequencing technologies on patient care is unclear. We have designed a
process of interpreting WGS results and delivering them to physicians in a way that anticipates how we envision
genomic medicine will evolve in the near future. That is, our WGS report provides clinically relevant information
while communicating the complexity and uncertainty of WGS results to physicians and, through physicians, to their
patients. This project will not only illuminate the impact of integrating genomic medicine into the clinical care of
patients but also inform the design of future studies.
Trial registration: ClinicalTrials.gov identifier NCT01736566
Keywords: Whole genome sequencing, Genome report, Genomic medicine, Translational genomics, Primary care,
Cardiomyopathy genetics
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The sequencing of the human genome has brought with
it the promise of a genomic revolution for clinical medi-
cine. Many already envision a time when each person’s
genome will be sequenced and available over the course
of the life span as a resource, providing guidance for per-
sonalized approaches to health maintenance and disease
prevention and treatment. Whole genome sequencing
(WGS) is the laboratory process of determining most, if
not all, of the 3 billion DNA base pairs across the 46 chro-
mosomes of an individual’s genome. The first human gen-
ome sequence in the year 2003 cost almost $3 billion and
took more than 10 years to complete [1]. The costs of se-
quencing have dropped significantly since then, and pa-
tients and physicians increasingly have access to WGS
services in research and clinical settings [2-10]. At the
same time, thousands of new genetic associations with hu-
man disease have been identified [11]. WGS can capture
much of this information in a single clinical test for an in-
dividual, thereby simultaneously delivering genetic results
for rare Mendelian diseases, common polygenic diseases,
and personalized pharmacogenomics-based medication
safety and efficacy.
The potential benefits of WGS seem substantial for a
health-care environment that is increasingly emphasizing
a more patient-centered, personalized, and preventative
approach to wellness. Genetically personalized strategies
might counteract the patient and physician frustrations
that sometimes stem from the one-size-fits-all paradigm
of evidence-based medicine [12]. However, certain factors
may obstruct the successful integration of WGS into clin-
ical care. First, laboratories must develop scalable pipe-
lines to sequence genomes, ensure the quality of WGS
data, define the validity and utility criteria that variants
should meet to be reported to physicians, and appropri-
ately interpret and deliver WGS results to physicians and
their patients [9]. Then, patients will look to their health-
care providers for guidance on how to interpret and act
on WGS information [13]. In the absence of evidence for
the clinical validity and utility of WGS in most clinical set-
tings, it is unknown how providers will use WGS results
in clinical care. Without adequate physician preparedness,
the introduction of such inherently complex and probabil-
istic risk information to the patient-physician encounter
may result in clinical chaos. The application of WGS to
large numbers of individuals thus has the potential to un-
cover unanticipated findings whose impact on clinical care
is, at present, impossible to quantify. The resulting confu-
sion, coupled with the instincts of patients and clinicians
to order additional medical tests, has the potential to in-
crease health-care costs and iatrogenic harm without in-
creasing value [14,15].
Nevertheless, the application of sequencing to an indi-
vidual’s health care is highly likely in one form or another.
Patients have expressed the desire to integrate genome-
wide information into the physician-patient relationship
and may even feel that physicians have an obligation to do
so [13]. The development of standards and procedures for
the use of WGS information in clinical medicine is thus
an urgent need [16], and yet there is insufficient evidence
and considerable uncertainty in how to do so [17,18].
With this state of the science in mind, we are conducting
the MedSeq Project: a feasibility study implementing two
randomized trials of WGS in clinical medicine. We have
designed a study protocol to enroll both physicians and
their patients as study participants, to sequence and inter-
pret patients’ genomes, and to deliver clinical genome re-
ports to physicians for use in clinical care. In this study,
the questions we seek to answer include the following:
How should a clinical molecular genetics laboratory
process and report WGS results to physicians and
their patients in an intelligible way without
oversimplifying the inherent complexity and
uncertainty of WGS data?
With education and appropriate support, will
non-geneticist physicians feel adequately prepared to
discuss and manage WGS results with their patients?
How will the delivery of WGS results, some with unclear
clinical significance, impact the actions, attitudes and
outcomes of patients and their physicians?
Below we describe the design of the MedSeq Project
protocol. In particular, we discuss the rationale for our
study design and describe our protocol for recruiting
physicians and patients to the study, randomly assigning
patient participants to receive WGS or standard of care,
educating physician participants about WGS, and measur-
ing the impact of introducing WGS into clinical medicine.
Methods/design
Models of genomic medicine
Genome sequencing will be integrated into clinical care in
many ways. It is already demonstrating clinical utility for
the diagnosis and treatment of certain cancers [5,19] and
rare diseases [2,3,20-22] and shows promise for use in in-
fectious disease outbreaks [23-25] and fetal diagnosis in
prenatal medicine [7,26]. The design of the MedSeq Pro-
ject models two archetypal scenarios for how WGS could
be integrated into clinical care. First, in situations in which
a patient presents with a particular family history, symp-
tom, or clinical syndrome, the genomic sequence may be
specifically interrogated for a genetic cause for that par-
ticular presentation, a scenario we call disease-specific
genomic medicine. In this scenario, analysis of the gen-
ome focuses on known or suspected variants in relevant
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sequencing of candidate genes is already common prac-
tice, and the interrogation includes rigorous evaluation
of novel variants that may have little or no prior expos-
ure in the scientific literature or in available databases.
At the same time, WGS may uncover incidental findings
not related to the original indication for sequencing
[27,28]. In a very different scenario in which the patient
is generally healthy and does not have a family history
suggestive of a genetic condition, the genome could be
sequenced as a part of routine preventive medicine. We
call this scenario general genomic medicine.W h e r e a s
disease-specific genomic medicine mirrors today’sp r a c -
tice in medical genetics of investigating the underlying
genetic etiology of a clinical presentation, general genomic
medicine is conceptually different from any genetics com-
monly practiced today. It more closely resembles current
population-based preventive screening measures in clin-
ical practice, such as newborn screening for metabolic
disorders and adult screening for breast, cervical, and
colorectal cancer. Among individuals without a specific
indication for WGS, general genomic medicine examines
the genomes for disease variants meeting an agreed-upon
threshold for clinical relevance. Given the higher risk of
false-positive test results in this generally healthy popula-
tion, general genomic medicine requires higher standards
of certainty and clinical significance. It also incorporates
well-established pharmacogenomic associations so that
clinicians can query a patient’s sequence for the likelihood
of drug efficacy and safety when a new medication is
prescribed. Moreover, carrier status results for recessive
Mendelian traits such as Tay-Sachs disease and cystic
fibrosis allow patients and their family members to
recognize the presence of carrier states and to consider
preconception screening or prenatal surveillance.
To model disease-specific genomic medicine,w ea r e
drawing on the expertise in the diagnosis, management,
and molecular etiology of hypertrophic and dilated cardio-
myopathy (HCM and DCM) among our study investiga-
tors at the Brigham and Women’s Hospital Cardiovascular
Genetics Center. To answer the question of how WGS
might impact the clinical care of HCM and DCM as com-
pared with standard of care, we are enrolling cardiologists
and their patients with HCM or DCM who have previ-
ously undergone or are preparing to undergo targeted
genetic testing for a panel of genes known to be associated
with cardiomyopathy. One example of such a standard
genetic test is the Partners Laboratory for Molecular Med-
icine’s Pan Cardiomyopathy Panel, a targeted interrogation
of 51 genes associated with conditions such as HCM,
DCM, arrhythmogenic right ventricular cardiomyopathy,
and left ventricular non-compaction [29]. To model
general genomic medicine, we are recruiting primary
care physicians (PCPs) and their generally healthy adult
patients from the network of primary care practices at
Brigham and Women’s Hospital, a network of more than
100 PCPs at 13 sites in the greater Boston area serving a
diverse patient population of almost 100,000. This model
of general genomic medicine uses WGS as an adjunct to
routine preventive care in a population of patients without
a specific indication for genetic testing.
Overview of study design
Figure 1 shows the MedSeq Project study schema. A ran-
domized controlled trial design enhances our ability to iso-
late the effect of WGS disclosure on patient and physician
attitudes and behaviors. Within each of the cardiology and
primary care trials, we randomly assign patient participants
to WGS versus standard of care and then study the impact
of disclosing this risk information to physician and patient
participants. The Partners Healthcare institutional review
board approved this study protocol.
Recruitment, enrollment, and sample size
We are recruiting a convenience sample of 8 to 12 PCPs
and 8 to 12 cardiologists specializing in cardiomyopathy
at our institution via individual and group e-mail com-
munication and informational presentations for individ-
ual providers and group practices. Once enrolled in the
study, each physician participant identifies and recruits 8
to 12 of his or her eligible patients, using study bro-
chures, letters, phone calls, and in-person conversations.
Potential patient participants are referred to study staff,
who confirm eligibility and obtain informed consent
during an in-person encounter. Our enrollment target is
200 total patient participants: 100 from primary care
and 100 from cardiology. The MedSeq Project is a feasi-
bility study that examines many outcomes; this targeted
sample size is not formally designed to achieve statistical
power for one specific primary outcome. Physician par-
ticipants are compensated for their time at the end of
the study regardless of the number of patients enrolled.
Patient participants are compensated at the end of the
study after completion of the 6-month survey and must
complete all study surveys to receive compensation. A
subset of patient participants is invited to complete quali-
tative interviews and receives additional compensation.
Patient and physician incentives are intended to minimize
losses to follow-up and occurrences of missing data.
Patient inclusion and exclusion criteria
Table 1 shows the inclusion and exclusion criteria of the
MedSeq Project patient participants. All patient partici-
pants must be receiving care from one of the physician
participants, all of whom are affiliated with our institu-
tion. Patient participants in the primary care trial are
generally healthy adults who are 40 to 65 years old. Pa-
tient participants in the cardiology trial have a diagnosis
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Figure 1 MedSeq project study schema. DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy.
Table 1 Overall inclusion and exclusion criteria of the MedSeq project patient participants, plus additional criteria
specific to the primary care or subspecialty cardiology trials
Both trials Primary care trial Cardiology trial
Inclusion criteria Patients receiving care from MedSeq
Project physician participants
Age 40-65 years Age 18-90 years
Generally healthy, in the judgment of
the patient’s participating physician
Diagnosis of hypertrophic
cardiomyopathy (HCM) or dilated
cardiomyopathy (DCM)
No indication for a genetic test Prior or concurrent targeted genetic
testing for HCM or DCM
Exclusion criteria Clinically significant anxiety (Hospital Anxiety and
Depression Scale [HADS] anxiety subscale >14)
or depression (HADS depression subscale >16)
at baseline assessment
Presence of cardiovascular disease
or diabetes
Reported current pregnancy or intention for
future conception in the next year of
participant or spouse/partner
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genetic testing for this condition. Any patient with a
score of more than 14 or more than 16 on the anxiety
and depression subscales, respectively, of the Hospital
Anxiety and Depression Scale (HADS) [30] is excluded
from enrollment; a study clinician explains the HADS
result to the patient and makes appropriate clinical re-
ferrals, as necessary.
Study arms
For comparison with the WGS arms, the control arms ap-
proximate the standard of care for the two clinical scenar-
ios under study. In routine primary care, the standard of
care for identifying the risk of heritable conditions is a
general family history assessment. In our cardiomyopathy
practice, the standard of care is a family history assess-
ment plus consideration of targeted genetic testing for
cardiomyopathy. At the baseline visit of the MedSeq Pro-
ject, patient participants complete a customized version of
the US Surgeon General’s “My Family Health Portrait”
web tool [31] to document the diseases diagnosed among
their family members. This web tool generates a family
history summary based on the patient-entered data. The
tool’s designers developed a workflow unique to our study
that securely transmits each patient participant’s family
history summary to the study staff, who forwards it to the
patient’s participating physician. Physician participants
also receive six clinical decision support modules to ac-
company the family history summary for each patient, to
assist them in interpreting and managing their patients’
heritable risk of breast and colon cancer, coronary artery
disease, type 2 diabetes, glaucoma, and osteoporosis. Pa-
tient participants in the control arms undergo only the
family history review with their physicians, whereas pa-
tient participants randomly assigned to the WGS arms
review both their family history summaries and WGS re-
sults with their physicians.
Physician education and support
Many physicians feel ill prepared to address genomic
medicine in their clinical practices [32-35], but the current
size of the genetics workforce makes it impractical to have
a genetic counselor or medical geneticist involved in every
instance of genomic medicine as more and more patients
are sequenced [36-38]. Moreover, as genomic medicine
finds utility in an increasing number of clinical contexts,
the most appropriate place for the integration of genomic
information may be the existing physician-patient rela-
tionship. That is, preventive medicine for healthy adults
appropriately belongs in primary care, and the manage-
ment of diseases such as cardiomyopathy belongs in
cardiology. To address the low self-efficacy in genomic
medicine that many physicians report, the MedSeq Project
provides participating PCPs and cardiologists with an
orientation to the study protocol and genome report at
the beginning of the study. The educational curriculum
consists of two 1-hour in-person group classes and 4
hours of self-paced online modules. The curriculum uses
case-based examples to cover general genetics concepts
such as inheritance patterns, an overview of Mendelian
conditions, genome-wide association studies and risk of
common complex diseases, and pharmacogenomics.
Participants may receive continuing medical education
credits for participation. The MedSeq Project also offers
individualized support to physician participants during
the course of the study. The MedSeq Project Genome
Resource Center (GRC) links physician participants via
telephone or e-mail to genetics counselors and medical
geneticists affiliated with the study, in a manner similar
to hotlines provided by state laboratories to support pe-
diatricians with questions about newborn screening re-
sults. Physician participants have the option to contact
the GRC with specific questions about the genome re-
ports or family history summaries of their participating
patients but are not required to do so. The GRC staff re-
cords the reasons that physician participants contact the
GRC and any recommendations or actions the GRC
staff takes as a result, using a web-based logbook with
RedCap™ software [39].
Whole genome sequencing and analysis
The MedSeq Project models the delivery of WGS in a trad-
itional clinical setting. That is, as in other tests ordered in
clinical care, a molecular genetics laboratory analyzes and
interprets the WGS data and delivers a report to the phys-
ician, who then discusses the results with the patient and
develops a management strategy. For the MedSeq Project,
genome sequencing is performed at the Illumina Clinical
Services Laboratory (San Diego, CA, USA) on the HiSeq
2000 platform [40]. Genomes are sequenced to at least 30×
mean coverage, with a minimum of 95% of bases se-
quenced to at least 8× coverage. Two blood samples are
collected from each patient participant; one is sent directly
to Illumina for sequencing, and the other is retained by the
Laboratory for Molecular Medicine (LMM) for individ-
ual variant confirmation, as needed. Once sequencing is
complete, Illumina transfers the sequence alignment
and variant calling data to the LMM for further analysis
via an encrypted hard drive. All analyses are performed
in laboratories approved by Clinical Laboratory Improve-
ment Amendments (CLIA).
The data files from each individual genome contain ap-
proximately 3 million variants. Geneticists at the LMM
prioritize the variants from each genome for further
analysis by using two different bioinformatics filtering
strategies. The Genome Report filter identifies (a) variants
classified as disease-causing mutations in the Human
Gene Mutation Database (HGMD) (professional version)
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site variants with a minor allele frequency of less than 5%
in European American or African American chromo-
somes from the National Heart, Lung and Blood Institute
Exome Sequencing Project [42]; (c) pharmacogenomic
variants associated with commonly used medications; and
(d) a subset of blood group antigens predicted by the gen-
ome sequence and confirmed via traditional serological
testing of a separate patient sample. In addition, patients
in the cardiomyopathy arm have another filter applied,
which identifies all variants in 102 preselected monogenic
cardiovascular disease genes. This includes variants that
would not be identified in filters (a) and (b) above. In the
Cardiac Risk Supplement, genotypes at a number of prede-
fined loci are returned for use in algorithms to define risk
status for common complex cardiovascular phenotypes.
The LMM staff reviews the scientific evidence for disease
causality for each variant that results from the filtering
strategies above, with the exception of the predefined set of
pharmacogenomics variants and common non-Mendelian
risk variants for common complex cardiovascular pheno-
types. For candidate monogenic disease variants, analysis
components include genetic and functional evidence from
primary scientific literature, allele frequency, conservation
of affected amino acid or nucleotide (or both), affected
protein domain, pathogenicity predictions, and splicing
predictions. Finally, each variant is classified according to
LMM criteria for pathogenicity [43]. Variants meeting cri-
teria for report inclusion as discussed in the subsequent
section are confirmed via a traditional Sanger sequencing
method using extracted DNA from the blood sample
retained by the LMM.
The genome report
In the MedSeq Project, the LMM delivers WGS results
to physician participants as a Genome Report and a
more exploratory Cardiac Risk Supplement, both de-
scribed below (Table 2) and exemplified in Additional
files 1 and 2. Because the target audience of these re-
ports consists of busy clinicians with variable expertise
in genetics, the results of the Genome Report are com-
pletely summarized on the first page of the report, and
subsequent pages contain greater detail about each re-
ported variant. The Genome Report includes results of
more general significance, including known pathogenic
or likely pathogenic Mendelian variants, carrier status
for Mendelian diseases, and known pharmacogenomics
associations for five commonly used medications. Owing
to the low prior probability of Mendelian disease among
the patient participants, variants of uncertain signifi-
cance (VUSs) in known Mendelian genes are included
on the Genome Report if available evidence favors
pathogenicity and if clinical follow-up may resolve the
variant’s significance or if the variant is in a gene associ-
ated with the etiology of the patient participant's disease
(HCM or DCM). Because of the frequency of clinical
decision-making around cardiovascular disease preven-
tion in primary care, we are using the Cardiac Risk Sup-
plement and cardiovascular disease to explore a wider
range of uncertainty in clinical utility than is present for
established Mendelian genes. Thus, to supplement the
Genome Report, the Cardiac Risk Supplement contains
common alleles associated with eight cardiometabolic
traits from genome-wide association studies (GWAS),
such as coronary artery disease, type 2 diabetes, and
atrial fibrillation. We are also piloting the use of a poly-
genic prediction model for lipid levels.
For the cardiometabolic phenotypes known to be rele-
vant both to primary care and cardiology practice, we
use GWAS results to aggregate risk information across
independent loci to convey a single summary of one’s
genetic risk for a given trait. For each trait, the Cardiac
Table 2 Categories of whole genome sequencing results that may be included in the genome report and cardiac risk
supplement in the MedSeq project
Genome report Cardiac risk supplement
Known pathogenic or likely pathogenic Mendelian variants, including some
high-grade variants of uncertain significance resolvable by clinical evaluation
Predicted lipid profile (fasting low-density lipoprotein and high-density
lipoprotein cholesterol and triglycerides) derived from polygenic model
Carrier status for Mendelian diseases Aggregate genetic risk associated with eight cardiometabolic traits from
genome-wide association studies
Pharmacogenomic associations for five commonly used medications: Aortic aneurysm
Warfarin Atrial fibrillation
Clopidogrel Coronary artery disease
Digoxin Hypertension
Metformin Obesity
Simvastatin Platelet aggregation
Genetic prediction of blood type with partial serological confirmation QT prolongation
Type 2 diabetes
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scores (MPRSs) derived from 161 published risk alleles
with small or moderate effects sizes (median odds ratio
1.14). We calculate the MPRS as the product of the odds
ratios per risk allele at each of several loci, each raised to
its count (that is, 0, 1, or 2). The Cardiac Risk Supple-
ment communicates this risk as a polygenic relative risk
and its decile after normalizing the MPRS by the popula-
tion median from the 379 Europeans in the 1000 Ge-
nomes Project [44].
Neither the Genome Report nor its Cardiac Risk
Supplement includes specific clinical recommenda-
tions on follow-up testing or referrals. This is consist-
ent with typical clinical laboratory reports and
important for the goals of the MedSeq Project, as we
hope to understand how clinicians contextualize and
use such information in their practices. The format of
the report may evolve over the course of the study,
depending on feedback from the physician partici-
pants, advances in genomic discovery, and the emer-
gence of more robust population data on which to
base clinical risk prediction. Reports are generated by
using the GeneInsight Laboratory software system and
transmitted to the GeneInsight Clinic system, which is in-
tegrated with our institution’s electronic health record
(EHR) [45].
Study schema
Figure 1 shows the study flow and data collection points
of the MedSeq Project. At the baseline visit with study
staff, patient participants complete the baseline surveys
and online family history assessment, undergo a blood
draw, and are block-randomized to either the WGS or
control arm. In the primary care trial, randomization is
sex-matched. In the cardiology trial, randomization is
stratified on the basis of previous targeted genetic testing
results, such that a known pathogenic variant will have
already been identified in approximately half of each
randomized arm. No molecular diagnosis has been made
for the remaining half, despite their having also undergone
targeted cardiomyopathy genetic testing as a part of
clinical care.
Once a patient’s family history summary and Genome
Report are prepared, generally after a couple of months,
they are sent to the physician participant, who then has
the option of contacting the GRC for assistance in inter-
preting the results. The study staff schedules a
one-on-one disclosure visit between the patient and
physician participants. At this disclosure visit, the
patient learns whether he or she was randomly
assigned to receive WGS. The patient discusses with
his or her physician the findings in the family history
summary and, if randomly assigned to receive WGS,
the Genome Report. The physician and patient
make management decisions about these findings as
they would in usual clinical care, which may include
pursuing additional follow-up testing or referrals to
subspecialists. The physician participant documents
the family history and WGS information and the
related clinical decision-making in the EHR as he or
she feels appropriate. The disclosure visits are audio-
recorded for qualitative analysis of physician-patient
communication.
Within 1 week after this visit, physician participants are
prompted by e-mail to complete a brief RedCap™ -based
checklist of the clinical actions they made as a result of the
family history summary and Genome Report for a given
patient. Patient participants are surveyed immediately after
the disclosure visit and 6 weeks and 6 months after disclos-
ure. A subset of 40 patient participants (approximately 10
in each arm of the two trials) undergoes semi-structured
interviews at enrollment and then 6 months after their
disclosure visits. Each physician participant undergoes
an interview at the beginning of the study before patient
enrollment and then again after conducting several dis-
closure visits.
Study outcomes
The MedSeq Project is leveraging multidisciplinary ex-
pertise and a diverse set of tools to collect and analyze
data on patients and physicians about a variety of out-
comes. Study outcomes focus on six broad domains identi-
fied as research priority areas across studies funded by the
National Human Genome Research Institute (NHGRI): (a)
attitudes and preferences, (b) understanding, (c) psy-
chological impact, (d) behavioral impact, (e) health-care
utilization, and (f) decisional satisfaction. When avail-
able, we use validated instruments and harmonize the
measurements across other NHGRI-funded studies of
the application of genome sequencing to clinical care.
Longitudinal measurements of many of these domains
allow us to examine changes over the study period.
Table 3 summarizes the specific outcomes being assessed
for each of these domains and the data sources used. Data
collection, including questionnaires, interviews, and audio-
recorded interactions with patients, is performed at
multiple time points. Paper and web-based surveys of
patient and physician participants provide self-reported
quantitative data about beliefs, attitudes, expectations,
psychological states, and intentions. Semi-structured in-
terviews with patients and physician participants allow
both groups to describe in their own words their motiva-
tions for participation, their attitudes and expectations,
and how they responded to results. Audio recordings of
the informed consent process and the results disclosure
encounter provide in vivo data about the kinds of ques-
tions that arise and issues that are discussed around WGS.
Physician checklists after each disclosure visit, logbooks of
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tient participant EHR data provide additional informa-
tion about service utilization, information seeking, and
health status. We believe this mixed-methods approach
allows us to achieve significant depth in chronicling the
impact of WGS information in the present trial while
simultaneously developing processes that will inform
the design of future trials. The MedSeq Project Publi-
cations Subcommittee has established guidelines for
publications and presentations and will review all publi-
cations and presentations for consistency with these
guidelines and will make recommendations to the Ex-
ecutive Committee regarding the dissemination of study
results to relevant stakeholder groups. We will report
results according to the CONSORT Statement and its
extension for non-pharmacologic treatment interven-
tions and will include a description of how missing data
were handled [46,47].
Discussion
The MedSeq Project consists of two randomized con-
trolled trials designed to model two archetypal situations
in genomic medicine and study the impact of integrating
genome sequencing into patient care. In the cardiology
trial, we want to know how WGS, with a particular focus
on cardiac risk information, might alter the ongoing clin-
ical management of cardiomyopathy patients. The cardi-
ology trial also allows us to study how physicians and
patients manage incidental genomic findings not directly
related to the original reason for genetic testing [27]. In
Table 3 Patient- and physician-oriented outcomes by domain and data source in the MedSeq project
Data source
Patient
surveys
Patient
interviews
Physician
surveys
Physician
interviews
Physician
checklist
Audio
recordings
EHR
review
GRC
logbook
Attitudes and preferences
Attitudes about project [48] ✓✓ ✓
Attitudes about sequencing [13] ✓✓ ✓
Perceived utility ✓✓ ✓ ✓ ✓
Preferences for information ✓✓
Understanding
Understanding of consent [49,50] ✓✓ ✓ ✓ ✓
Understanding of results ✓✓ ✓
Genetic self-efficacy [51] ✓✓
Genetic literacy [52] ✓✓ ✓ ✓
Health and risk perceptions [53] ✓
Psychological impact
General anxiety and depression [30] ✓
Results-specific affect [54] ✓
Intolerance of uncertainty [55] ✓
Behavioral impact
Health behaviors and intentions [56] ✓✓ ✓
Insurance coverage [57] ✓✓
Medication and supplement use ✓✓ ✓ ✓
Information seeking and sharing [58] ✓✓ ✓ ✓ ✓
Health-care utilization
Willingness to pay ✓✓
Shared decision-making [59] ✓✓ ✓ ✓
Follow-up testing and screening [60] ✓✓ ✓ ✓ ✓✓ ✓
Decisional satisfaction
Satisfaction [61] ✓✓ ✓
Decisional regret [62] ✓✓ ✓
Expectations ✓✓ ✓
References indicate published scales used in the design of the data collection instruments for the MedSeq Project. EHR, electronic health record; GRC, Genome
Resource Center.
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shape the attitudes, behaviors, and health care of generally
healthy individuals. To answer these questions, we have
developed a scalable pipeline to analyze and interpret
WGS results and deliver a clinically useful genome report
to physicians caring for these patients. We provide
non-geneticist physician participants with educational
and consultative resources that we believe comprise a
workable model to support their use of genomic medi-
cine in an era when the demand for genetics specialists
exceeds supply.
The design of the MedSeq Project reflects many of the
competing priorities inherent in a study of integrating
WGS into clinical practice. We know that the field of
genomics itself is rapidly evolving over the course of the
study, let alone by the time the study’s results are ready
for dissemination. This evolution is occurring on many
fronts: improvements in sequencing quality, decreasing
costs and time necessary to perform sequencing, increas-
ing clinical experience with WGS at many academic med-
ical centers, and continual publication of newly discovered
genes and variants linked to human disease. Meanwhile,
we are limited by the present technology, costs, and know-
ledge at the time of study design. We understand that the
study of such a moving target risks the collection of re-
sults that could rapidly become obsolete, and thus we have
modeled processes for the integration of WGS into clin-
ical medicine both now and in the near future. For ex-
ample, while we are generating genome reports based on
the current state of the science and delivering them to the
physician-patient encounter, we plan to allow the format
and content of these reports to evolve with the field,
incorporating new discoveries and refining our interpreta-
tions of pathogenicity and utility. We hope to create a
paradigm for the clinical integration of WGS which will
remain relevant even as genomic medicine advances in
technology and content.
We also are attempting to integrate the clinical uncer-
tainty that necessarily accompanies results from WGS,
particularly in healthy adults, and at the same time
present a meaningful genome report to physicians and
their patients. When clinical significance is uncertain,
the report will have to acknowledge and communicate
this uncertainty effectively, allowing the physician to
contextualize the information for the individual patient.
This tension necessitates finding the right balance be-
tween embracing the ambiguity of WGS results and lim-
iting the scope of what is reported to physician and
patient participants. The importance of cardiovascular
disease in primary and subspecialty care has prompted
us to explore, through the Cardiac Risk Supplement, a
greater degree of genomic uncertainty in that disease
area as a demonstration of integrating GWAS-type re-
sults into clinical care.
In addition, we seek to balance the tensions of providing
enough support to participating physicians while minimiz-
ing the burden to the limited genetics referral resources
available at most medical centers. We have designed the
MedSeq Project with the premise that all physicians will
soon have to manage at least some genomic information
in their practices. Thus, we have intentionally not pro-
vided a level of counseling or consultant support that
would make our model logistically or economically unsus-
tainable as WGS is increasingly introduced to the clinical
context. Still, we acknowledge the need to provide at least
some educational and consultation support, both to en-
sure the quality of care in this novel situation and to
monitor for patient safety. We believe that the product of
these tensions, the MedSeq Project educational curricu-
lum and Genome Resource Center, represents a workable
model for physician support in genomic medicine re-
search, with potential for scaling to routine clinical use.
Our study has some limitations inherent in a trial of
this nature. Because we are studying the way that new
genomic information is used in clinical care, we cannot
blind our patient and physician participants to their
randomization status. Unblinded randomized controlled
trials may be biased by changes in patient and physician
behaviors and outcomes unrelated to the effect of the
intervention studied. In our case, however, these changes
in behaviors and outcomes are precisely what we are inter-
ested in studying. Similarly, our researchers are not
blinded to patient randomization. For this reason, our use
of objective survey instruments and EHR data is particu-
larly helpful in comparing those who received WGS with
those who did not. Finally, each physician participant in
the study will have patients in each of the two study arms.
Our results will therefore have to be interpreted with the
risk that patient outcomes may be correlated with phys-
ician behavior in mind. As appropriate, we will perform
certain analyses with clustering by physician to account
for these possible within-physician effects.
The MedSeq Project is the first randomized con-
trolled trial of WGS in clinical care. We are using a
multidisciplinary team of laboratory and clinical geneti-
cists, bioinformaticians, biostatisticians, clinicians, and
social scientists to study the many ways that WGS will
impact patient care in two archetypal clinical scenarios:
disease-specific genomic medicine and general genomic
medicine. We expect to produce quantitative and quali-
tative data that inform the ongoing real-time clinical
integration of WGS and also generate novel hypotheses
to inform the design of larger studies moving forward.
Our considerations of how best to present complex but
clinically relevant information derived from WGS to
physicians and their patients and measure its impact on
clinical care should remain instructive for future re-
search in genomic medicine.
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Physician and patient participants were being enrolled as
of March 2014.
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